Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05742841 · ClinicalTrials.gov registry record · Phase 4
EMERALD (Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders)
A Phase 4 study of Lipid Disorder, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 4
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT05742841: Completed Phase 4 study of Lipid Disorder, sponsored by Wake Forest University Health Sciences.
NCT05742841 is a Phase 4 study of Lipid Disorder that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 22 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05742841, a Phase 4 study of Lipid Disorder, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
The EMERALD intervention involves 1) ordering an Emergency Department (ED) lipid panel, 2) calculating 10-year Atherosclerotic cardiovascular disease (ASCVD) risk using the Pooled Cohort Equations, 3) prescribing a moderate- or high-intensity statin if applicable, and 4) referring patients to outpatient care (primary care, preventive cardiology, or general cardiology, depending on risk level).
Primary Outcome
A lipid panel is a common blood test that healthcare providers use to monitor and screen for risk of cardiovascular disease. The panel includes three measurements of your cholesterol levels and a measurement of your triglycerides.
Conditions Studied
Interventions
- DRUG moderate- or high-intensity statin/ rosuvastatin
Study Locations (1)
North Carolina
- Wake Forest University Health Sciences - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2023-03-08 |
| Est. Completion | 2023-07-15 |
| Phase | Phase 4 |
What the finished NCT05742841 record still lists
NCT05742841 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Lipid Disorder appearing as the primary indexed condition, and to 1 intervention - of which moderate- or high-intensity statin/ rosuvastatin is the first listed.
NCT05742841 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT05742841 about?
NCT05742841 is a clinical study titled "EMERALD (Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders)". The EMERALD intervention involves 1) ordering an Emergency Department (ED) lipid panel, 2) calculating 10-year Atherosclerotic cardiovascular disease (ASCVD) risk using the Pooled Cohort Equations, 3) prescribing a moderate- or high-intensity statin if applicable, and 4) referring patients to outpat...
What is the current status of trial NCT05742841?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 22 participants. The study started on 2023-03-08. Estimated completion is 2023-07-15.
What conditions does trial NCT05742841 study?
This clinical trial studies the following conditions: Lipid Disorder.
What interventions are being tested in trial NCT05742841?
The interventions under investigation include: moderate- or high-intensity statin/ rosuvastatin (DRUG).
Who is sponsoring clinical trial NCT05742841?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05742841 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lipid Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05742841's enrollment target sits among peer trials
22 1731st of 2000 higher than 260 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI